Skip to content

Bausch Health Companies BHC Salix — Goodwill, impairment loss

Other segment segments

Bausch + Lomb
$0
Diversified
$0-100%
International
$0
Solta Medical
$0

Similar metrics at other companies

CSW Industrials, Inc. logo
CSWSpecialized Reliability Solutions — Goodwill, Impairment Loss
$0
Cardinal Health logo
CAHPharmaceutical and Specialty Solutions — Goodwill, Impairment Loss
$184M
Horace Mann Educators logo
HMNSupplemental & Group Benefits — Goodwill, Impairment Loss
$0
DENTSPLY SIRONA logo
XRAYEssential Dental Solutions — Goodwill, Impairment Loss
$0
DENTSPLY SIRONA logo
XRAYWellspect Healthcare — Goodwill, Impairment Loss
$0
Calumet, Inc. logo
CLMTSpecialty Products And Solutions — Goodwill Impairment
$0

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$1.86B-15.9%

Profitability

See full
Gross margin71.4%
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%
Debt / equity45.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:GoodwillImpairmentLoss.

The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch Health Companies's salix — goodwill, impairment loss.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch Health Companies's salix — goodwill, impairment loss?
Bausch Health Companies (BHC) reported salix — goodwill, impairment loss of $1.43B in Q1 2026.
What does salix — goodwill, impairment loss mean?
Measures the reduction in the carrying value of goodwill within the Salix segment when its fair value falls below its book value. This charge indicates that the expected future economic benefits from previous acquisitions in this segment have declined. It serves as a critical indicator of potential overpayment for past assets or deteriorating market conditions in the gastroenterology sector.